The specific intracellular cyclic AMP-dependent protein kinase antagonist, the Rp-diastereomer of adenosine cyclic 3',5'-phosphorothioate (Rp-cAMPS), inhibited both basal and cyclic AMP-agonist-induced rates of gluconeogenesis in hepatocytes isolated from fasted rats. Incubation of the cells in the presence of pyruvate and lactate and either the Sp-diastereomer of adenosine cyclic 3',5'-phosphorothioate (Sp-cAMPS) or glucagon produced a concentration-dependent increase in the rate ofgluconeogenic glucose production which was shifted to higher concentrations of Sp-cAMPS or glucagon in the presence of Rp-cAMPS. Incubation of the cells with Rp-cAMPS in the absence of agonist produced no increase in the rate of glucose production and, in most cases, 100 liM-Rp-cAMPS resulted in a 14-20% decrease in the substrate-stimulated rate of glucose production. Sp-cAMPS-induced gluconeogenesis was inhibited half-maximally at 1 gM-Rp-cAMPS and glucagon-induced gluconeogenesis was inhibited half-maximally at 12,uM-Rp-cAMPS. Approx.10-15% of the inhibition of gluconeogenesis observed in the presence of Rp-cAMPS was due to conversion of glucose 6-phosphate to liver glycogen, consistent with Rp-cAMPS-induced reactivation of glycogen synthase. The remaining 85-90% inhibition of gluconeogenic glucose production resulted from the action of Rp-cAMPS on the cyclic AMP-sensitive enzymes controlling the rate of gluconeogenesis.
INTRODUCTION
The diastereomers of adenosine cyclic 3',5' phosphorothioate, S -cAMPS and Rp-cAMPS, have been shown to have dif?erential effects on the activity of cyclic AMP-dependent protein kinase (deWit et al., 1982; O'Brien et al., 1982; Rothermel et al., 1983) , phosphorylase and glycogen synthase , and pyruvate kinase (Meserve et al., 1985) . Sp-cAMPS is a cyclic AMP-dependent protein kinase agonist which binds to, and activates, both Type I and Type II holoenzymes. Rp-cAMPS is a cyclic AMP-dependent protein kinase antagonist which is unique in being the first reported cyclic AMP analogue which competes with cyclic AMP for the binding sites on the regulatory subunit without causing dissociation of the holoenzyme. Since this analogue also crosses the hepatocyte membrane rapidly, Rp-cAMPS is the first available inhibitor of cyclic AMP-dependent protein kinase which can be added to cell preparations to inhibit specifically intracellular cyclic AMP-dependent biochemical events. In hepatocytes isolated from fed rats, Rp-cAMPS inhibits the Sp-cAMPS-induced (Rothermel et al., 1983) and glucagon-induced activation of cyclic AMP-dependent protein kinase and the consequent effects of phosphorylation of the enzymes controlling both the glycogenolytic cascade (Rothermel et al., 1984 and glycolysis (Meserve et al., 1985) . Rp-cAMPS alone does not affect the basal activities of cyclic AMP-dependent protein kinase, phosphorylase, glycogen synthase or pyruvate kinase in cells isolated from fed rats (Meserve et al., 1985; Rothermel et al., 1983 Rothermel et al., , 1984 Rothermel et al., , 1985 .
The present paper presents the effects of Rp-cAMPS on gluconeogenesis in hepatocytes isolated from fasted rats.
It is argued that the antagonistic effects of Rp-cAMPS on basal and agonist-induced rates of gluconeogenesis are due to the inhibition of cyclic AMP-dependent protein kinase and the subsequent effects of this inhibition on pyruvate kinase activity, glycogen synthase activity and glycogenesis.
EXPERIMENTAL

Materials
Crystalline glucagon, UDP-glucose and gl-ycogen were obtained from Sigma. Collagenase (EC 3.4.24.3; diopeptidase A) was purchased from Worthington (CLS II, 133 units/mg; 1 enzyme unit equals 1 smol ofL-leucine equivalents from collagen in 5 h at 37°C and pH 7.5).
The phosphorothioates Rp-cAMPS and Sp-cAMPS were prepared as published previously by Stec and co-workers (Baraniak et al., 1979) , and in order to reach diastereomeric purity and to eliminate traces of cyclic AMP, were repurified by h.p.l.c. on a reverse phase C-18 column using separation conditions optimized according to Van Haastert (1981) . UDP-[U-14C]glucose and Aquasol were obtained from New England Nuclear. All other chemicals were reagent grade.
Methods
Liver parenchymal cells were isolated from 18-20 h fasted male Sprague-Dawley rats that were maintained on a 12 h light/ 12 h dark cycle in an environmentally controlled room. Cells were prepared according to a modification of a procedure of Berry & Friend (1969) .
The stock solution used for cell isolation was a Ca2+-free Hepes (20 mm, pH 7.4) buffer containing 136 mM-NaCl. 4.7 mM-KCl, 1.2 mM-KH2PO4, 0.7 mM-MgSO4, 24 mmNaHCO3 and 20 mM-glucose. This solution was gassed with 02/CO2 (19: 1) for 1 h at 35°C immediately prior to use. The liver was perfused via the hepatic portal vein first with the stock Hepes buffer containing 0.5 mM-EGTA for 10 min and then with the stock buffer containing collagenase (26.6 units/ml) and 5 mM-CaCl2 for 20 min. The tissue was then removed and rapidly minced in the stock Hepes buffer and filtered through nylon mesh. The hepatocyte suspension was centrifuged at slow speed and the resulting soft pellet was washed three times in an incubation buffer comprised of 20 mM-Hepes (pH 7.4), 123 mM-NaCl, 5 mM-KCl, 2 mM-MgSO4, 2.5 mM-K2HPO4, 0.8 mM-CaCl2, 24 mM-NaHCO3, 60 #M-penicillin, 2% (w/v) bovine serum albumin and 3.25% (w/v) dextran. Only preparations demonstrating greater than 90% cell viability as determined by Trypan Blue exclusion and microscopic observation of the cell membranes were used in the experiments described in this paper.
Each 20 ml vial contained hepatocytes at a concentration of 1 x 107 cells/ml of incubation buffer and all experiments were performed at 30°C in a Dubnoff metabolic shaker after a 30 min equilibration period under 02/CO2 (19: 1). All additions to the cell suspensions were prepared in the incubation buffer. R -cAMPS was added to the cell suspensions at -20 min wlen glucagon was used as the cyclic AMP-dependent protein kinase agonist, and at either -20 min or 0 min when Sp-cAMPS was used as the agonist. At -5 min, a mixture of the gluconeogenic substrates, pyruvate and lactate, were added so that their incubation concentrations were 8 mm and 2 mm, respectively. Glucagon or Sp-cAMPS was added at 0 min. Cells were incubated for 1 h, during which time aliquots of cell suspension were removed for determinations of glycogen synthase, cyclic AMP-dependent protein kinase, glucose, lactate and glycogen.
For the determination of glycogen synthase activity, 70,tl aliquots of cell suspension were transferred to an equal volume of ice-cold buffer containing 10 mM-Mops (pH 7.0), 400 mM-sucrose, 5 mM-dithiothreitol, 0.03% (v/v) Triton X-100, 20 mM-EDTA and 150 mM-NaF at a final concentration of 5.0 x 103 cells/#l and were immediately frozen in an acetone/CO2 bath. Glycogen synthase activity was assayed according to Thomas et al. (1968) with some modifications as follows: 50,l of thawed, suspended cell mixture (equivalent to 0.165 mg dry weight) were incubated in an equal volume of buffer containing 20 mM-Mops (pH 7.0), 80 mM-sucrose, 1 mMdithiothreitol, 4 mM-EDTA, 30 mM-NaF, 1 % (w/v) glycogen, 6.7 mM-UDP-glucose with UDP-[14C]glucose (0.04,Ci/,mol). Reactions were terminated as described by Gilboe et al. (1972) and counted in Aquasol.
For the determination of cyclic AMP-dependent protein kinase activity, 300 ,l aliquots of cell suspension were treated as described previously (Rothermel et al., 1984) .
For the determination of glucose or lactate and glycogen, 400,1 aliquots ofcell suspension were removed to ice-cold Microfuge tubes and centrifuged at 8000 g for 5 s. The supematant was immediately removed and assayed for glucose and lactate concentrations with a Technicon AutoAnalyzer II. The pellet was immediately frozen in an acetone/CO2 bath for glycogen determination according to Huijing (1970) .
The mixture of gluconeogenic substrates chosen maintained a cytosolic NADH: NAD+ ratio sufficient for linear rates of gluconeogenesis over a 60 min time course (Williamson et al., 1969) . It has been shown that rates of gluconeogenesis and the magnitude of hormonal stimulation remain constant in spite of changes in the ratio of lactate to pyruvate over a wide range of concentration, but the use of either agent as the sole substrate leads to abnormal effects. For example, the lag period observed in the rate of glucose production with 15-20 mM-lactate can be overcome by adding as little as 2 mM-pyruvate, and the initial inhibition of 20 mM-pyruvate-induced gluconeogenesis obtained in the presence of cyclic AMP or glucagon can be overcome by the addition of as little as 3 mm-lactate (Clark & Janett, 1978; Garrison & Haynes, 1973; Rognstad, 1975; Zahlten et al., 1973) . Preliminary experiments established that, of several concentration combinations tried, 8 mM-pyruvate and 2 mM-lactate gave the highest rate of linear glucose production over 60 min in the presence of 0.3 /tM-Sw-cAMPS or 0.3 nM-glucagon. Glucagon was used as the agonist in a similar series of experiments. Maximal glucose production obtained in the presence of 1 nM-glucagon was 47-144O% higher than control levels measured over a 60 min time course in eight separate experiments. Half-maximal activation of glucose production was obtained at 0.07 nM-glucagon and this value was shifted to 7-fold higher concentrations of glucagon in the presence of 1O,tM-R -cAMPS and to 31-fold higher concentrations of glucagon in the presence of 100 1M-RP-cAMPS. In the experiment shown in Fig.   2 , a concentration of 100 lOm-R -cAMPS inhibited the p | basal rate of substrate-induced gYuconeogenesis by 20%
8.5 8 7.5 in the absence of glucagon. The glucose production data shown in Fig. 2 are from the 60 min point. 6-phosphate and that in the control the other 10-15% was due to an activation ofthe pathway MPS alone was from glucose 6-phosphate to glycogen. duction by 50°% at 1,UM and by 125% (maximal inhibition) at 100#/M (Fig. 3a) . Rp-cAMPS inhibited glucagon-induced glucose production by 5000 at 12 /UM and by 950 (maximal inhibition) at 300 ,UM (Fig. 3b) . The concentrations of Sp-cAMPS and glucagon chosen for this experiment were those observed to produce 80-100% of maximal glucose production.
DISCUSSION
The cyclic AMP antagonist Rp-cAMPS inhibited agonist-stimulated rates ofgluconeogenesis and depressed the basal rate of gluconeogenesis in hepatocytes isolated from fasted rats. The inhibition of glucagon-and Sp-cAMPS-stimulated gluconeogenesis in the presence of added pyruvate and lactate is consistent with inhibition of cyclic AMP-induced effects on the rate-limiting enzymes which control gluconeogenic glucose production.
The correspondence between the increased cyclic AMPdependent protein kinase activity following glucagon challenge and the increased rates of gluconeogenesis has been thoroughly examined (for a comprehensive review see Hers & Hue, 1983) and all phosphoprotein substrates of cyclic AMP-dependent protein kinase have been considered as candidates for the rate-controlling step in the gluconeogenic pathway. Five such substrates are rate-limiting enzymes controlling two important substrate cycles in the gluconeogenic pathway, namely, the fructose 1,6-bisphosphate/fructose 6-phosphate cycle and the pyruvate/phosphoenolpyruvate cycle. Recent experiments using a rat liver cell perifusion technique (Groen et al., 1983) showed that glucagon stimulation of gluconeogenesis in the presence of subsaturating concentrations of gluconeogenic substrates can be accounted for almost completely by inhibition of pyruvate kinase, with no measurable effect on the kinetic parameters of the enzymes operating in the gluconeogenic pathway between phosphoenolpyruvate and glucose. In the absence of glucagon, the rate of glucose production was maintained by both pyruvate kinase and pyruvate carboxylase. No rate-limiting control was observed at the mitochondrial pyruvate translocator step. The major control point has been postulated by these authors to be inhibition of pyruvate kinase.
In the present study, with hepatocytes isolated from 24 h fasted rats, glucagon and Sp-cAMPS increased the rates of gluconeogenic glucose production and the cyclic AMP antagonist Rp-cAMPS inhibited these effects. Rp-cAMPS has previously been shown to inhibit glucagon-induced and Sp-cAMPS-induced kinetic changes in pyruvate kinase activity (Meserve et al., 1985) and in glycogen synthase and phosphorylase activities through inhibition of cyclic AMP-dependent protein kinase (Rothermel et al., 1983 (Rothermel et al., , 1984 . Thus, in cells from fasted animals where gluconeogenesis dominates and the intensity of cycling at both the fructose 6-phosphate to fructose 1,6-bisphosphate step and the phosphoenolpyruvate to pyruvate step is controlled by cyclic AMP-dependent mechanisms (Hers & Hue, 1983) , the inhibition ofcyclic AMP-dependent protein kinase by Rp-cAMPS would be expected, in turn, to inhibit gluconeogenic glucose production. Analysis of the inhibitory effects ofRp-cAMPS shows that 85-90% ofthe Rp-cAMPS inhibition of Sp-cAMPS-and glucagoninduced gluconeogenic glucose production could be accounted for through inhibition of the pyruvate to glucose 6-phosphate pathway and an additional 10-150% through activation of glycogen synthesis (Table 1) (Katz et al., 1983; Newgard et al., 1984; Radziuk & Inculet, 1983) . That
Rp-cAMPS had a greater effect on the amount of glucose stored as glycogen in the Sp-cAMPS-treated cells versus the glucagon-treated cells seems to be a result of the greater inhibitory effect on the cyclic AMP-dependent protein kinase activity ratio in the Sp-cAMPS samples, despite the fact that the effect on glycogen synthase was not as great.
The Rp-cAMPS-induced effect on gluconeogenic glucose production from a mixture of pyruvate and lactate was not limited to inhibition of only the agonist-induced rates, but resulted in an additional 14-20% decrease in the unstimulated rate of glucose production. This additional inhibitory effect on the basal rates of glucose production resulted from R -cAMPS inhibiton ofthehigherendogenouscyclicAMP-Jependent protein kinase activity (Table 1) resulting from the increased cyclic AMP levels in hepatocytes isolated from fasted rats (Goldstein & Curnow, 1978) . In summary, the intracellular inhibitor of cyclic AMP-dependent protein kinase, Rp-cAMPS, inhibited substrate-induced gluconeogenesis in hepatocytes isolated from fasted rats in both the absence of cyclic AMP-stimulatory agents and in the presence of glucagon and the cyclic AMP agonist, Sp-cAMPS. Rp-cAMPS inhibited the production of glucose from added pyruvate and lactate both through inhibition of the synthesis of glucose 6-phosphate and through activation of the glycogen synthesis pathway. All of the effects on gluconeogenic glucose production may be attributed to inhibition of cyclic AMP-dependent protein kinase.
